Keros Therapeutics, Inc. has appointed Yung H. Chyung, M.D. as its Chief Medical Officer effective November 1, 2024. The company is focused on developing and commercializing novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins.
Dr. Chyung's appointment comes at a critical point for Keros as they prepare to initiate a phase 3 clinical trial evaluating elritercept (ker-050) in patients with lower-risk myelodysplastic syndromes. Furthermore, important data readouts for cibotercept (ker-012) and ker-065 are expected in 2025.
Dr. Chyung brings valuable experience, having previously served as the Executive Vice President and Chief Medical Officer of Tourmaline Bio, Inc. from August 2022 to October 2024, and as the Chief Medical Officer of Scholar Rock Holding Corporation from February 2016 to June 2022. He also held positions at Dyax Corp and Genzyme Corporation.
Keros' lead product candidate, elritercept, is being developed for the treatment of low blood cell counts, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. The company's second product candidate, cibotercept (ker-012), is aimed at treating pulmonary arterial hypertension and cardiovascular disorders, while the third product candidate, ker-065, is focused on the treatment of obesity and neuromuscular diseases.
This move aligns with Keros' commitment to advance its clinical programs, leveraging Dr. Chyung's expertise in TGF-ß superfamily and development. Today the company's shares have moved 0.8% to a price of $60.87. For more information, read the company's full 8-K submission here.
